Overview of Dr. Giaccone
Dr. Giuseppe Giaccone is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, New York-Presbyterian Hospital, and New York-Presbyterian Hospital. He received his medical degree from University of Torino Faculty of Medicine and has been in practice 37 years. He is one of 378 doctors at New York-Presbyterian Hospital and one of 378 doctors at New York-Presbyterian Hospital who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
520 East 70th Street
New York, NY 10021
Education & Training
University of Torino Faculty of MedicineClass of 1980
Certifications & Licensure
NY State Medical License 2019 - 2025
DC State Medical License 2013 - 2020
MD State Medical License 2007 - 2020
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013
Clinical Trials
- Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations Start of enrollment: 2016 Oct 01
- Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2017 Nov 20
Publications & Presentations
PubMed
- 74 citationsQuantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30Lars R. Perk, Marijke Stigter-van Walsum, Gerard W. M. Visser, Reina W. Kloet, Maria J. W. D. Vosjan
European Journal of Nuclear Medicine and Molecular Imaging. 2008-05-20 - 2818 citationsThe IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.Peter Goldstraw, Kari Chansky, John Crowley, Ramón Rami-Porta, Hisao Asamura
Journal of Thoracic Oncology. 2016-01-01 - 1243 citationsUsing Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted DrugsMark G. Kris, Bruce E. Johnson, Lynne D. Berry, David J. Kwiatkowski, A. John Iafrate
JAMA. 2014-05-21
Journal Articles
- Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLCRoy S Herbst, Giuseppe Giaccone, David R Spigel, The New England Journal of Medicine
Other
- Acquired SETD2 Mutation and Impaired CREB1 Activation Confer Cisplatin Resistance in Metastatic Non-Small Cell Lung CancerGiuseppe Giaccone, MD, Nature
https://www.doximity.com/articles/ce2cf164-045a-4837-ae67-370b24de031c
UpToDate, Wolters Kluwer Health - 2013-04-09
Press Mentions
- Q&A with Dr. Mario Gaudino, Newly Appointed Director of the Joint Clinical Trials OfficeJanuary 29th, 2021
Yale Trial Validates Immunotherapy Treatment for Non-Small Cell Lung CancerSeptember 28th, 2020- OSE Immunotherapeutics Presents Positive Step-1 Phase 3 Results for Tedopi® in NSCLC at the European Society for Medical Oncology Virtual Congress 2020September 21st, 2020
- Join now to see all
Committees
- Member (Steering committee), Update Committee of the ASCO NSCLC Expert Panel, American Society of Clinical Oncology 2015 - Present
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
